Clinical Trials Logo

Heart Diseases clinical trials

View clinical trials related to Heart Diseases.

Filter by:

NCT ID: NCT05104307 Completed - Heart Diseases Clinical Trials

Echocardiogram and Cardiac Performance System (CPS) Ejection Fraction Validation Study

Start date: November 9, 2021
Phase:
Study type: Observational

Non-significant risk device study to conduct evaluation of the performance of new device for monitoring of cardiac function (based on previous iterations 510(k) 173156)

NCT ID: NCT05103774 Not yet recruiting - Clinical trials for Value of Thyroid Functions in Children With Congenital Heart Diseases

Thyroid Functions in Children With Congenital Heart Diseases

Start date: December 1, 2021
Phase:
Study type: Observational

Thyroid hormone is critical for normal neurocognitive development in young infants, and even transient hypothyroidism can cause adverse neurodevelopmental outcomes. In a population of infants with CHD who already bear a high risk of long-term developmental delay, detection of hypothyroidism, even of a transient nature, may be even more consequential, and routine periodic monitoring of thyroid function may be necessary to reduce the risk of neurodevelopmental disabilities

NCT ID: NCT05103397 Recruiting - Anesthesia Clinical Trials

High Dose Methylprednisolone Verses Low Dose in Correction of Congenital Acynotic Heart Disease

Start date: October 16, 2021
Phase: Phase 4
Study type: Interventional

To compare the effect of low dose methylprednisolone versus high dose on inflammatory mediators' level and cardioprotective effect after CPB in correction of congenital acyanotic heart disease.

NCT ID: NCT05101746 Enrolling by invitation - Clinical trials for Congenital Heart Disease

Nitric Oxide Effect on Brain and Kidney in Pediatric Patients Undergoing Cardiopulmonary Bypass

Start date: April 25, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

The goals of this study are: 1. To evaluate the neuroprotective effect of nitric oxide by measuring glial fibrillary acid protein (GFAP) before and after surgery. GFAP will be analyzed via an enzyme-linked immunosorbent assay (ELISA) kit. Patients will also be monitored post-operatively for delirium in the intensive care unit (ICU). 2. To evaluate the renal protective effect of nitric oxide by measuring neutrophil gelatinase-associated lipocalin (NGAL) before and after surgery. NGAL will also be analyzed via an ELISA kit. Patient creatinine will be monitored post-operatively. 3. To evaluate effect of nitric oxide on other ICU outcomes (invasive mechanical ventilation, days to extubation, ICU and hospital length of stay, and blood product administration).

NCT ID: NCT05099692 Recruiting - Clinical trials for Coronary Heart Disease

CHD Patient's Concern on Cardiac Rehabilitation

Start date: October 15, 2021
Phase:
Study type: Observational

Our study focuses on the question about primary cardiac rehabilitation (CR) patients with coronary heart disease are concerned about demonstrating the association between the patients' view of CR and social associated factors. In our study, all participants are invited to choose at least 1 question in 15 questions or provide their questions regarding their doubt about the CR after filling in their personal information. The selectable questions can be categorized into five titles: the content or purpose of CR, the method of CR, the advantage of CR, the adverse effect of CR, and the expenditure of CR.

NCT ID: NCT05092711 Recruiting - Clinical trials for Ischemic Heart Disease

Cardiovascular Risk Factors , Complications and Threputic Management Strategies in Patients With Coronary Heart Disease and COVID 19

Start date: July 1, 2022
Phase:
Study type: Observational

Using INTERASPIRE model to determine patients with established CHD whether the guidelines on cardiovascular disease prevention are being followed or not with incorporation of COVID 19 as a risk factor with the other classical risk factors to understand significance of the new pandemic virus in mortality and morbidity of CVD and coronary events in association with the other known classical risk factors .

NCT ID: NCT05090748 Completed - Cardiac Disease Clinical Trials

Study for the Assessment of the Quality of Echocardiographic Clips.

Start date: May 15, 2022
Phase:
Study type: Observational

This study main objective is to evaluate the safety and efficacy of the UltraSight AI Guidance software. The investigational product is a software that guides the user to capture a high quality ultrasound image. The study will include healthcare professionals, not specialized in echocardiography, who will perform echocardiography by using UltraSight AI Guidance software, on subjects in the medical centers cardiac units.

NCT ID: NCT05090306 Recruiting - Clinical trials for Congenital Heart Disease

Interpretation of Fetal Echocardiography by Artificial Intelligence

LIFE
Start date: November 1, 2020
Phase:
Study type: Observational

The study to be performed aims to design and develope an automated Intelligent Decision Support System for fetal echocardiography that can significantly assist the obstetric physician in the improvement of detection of fetal congenital heart disease compared to the common standard of care.

NCT ID: NCT05089136 Active, not recruiting - Clinical trials for Valvular Heart Disease

Transcatheter Para-Valvular Leak Closure: An International Prospective Multicentre Registry

FFPP1
Start date: January 1, 2017
Phase:
Study type: Observational [Patient Registry]

Prosthetic paravalvular leaks (PVL) leading to heart failure and/or haemolysis can be treated by interventional cardiology or open-heart surgery. Predictors of clinical success of transcatheter closure remains little known and should be identified to help choose between these two options.Patient selection criteria for the best option are needed. The investigators aimed to identify predictors of clinical success after transcatheter PVL closure. Consecutive patients referred to 24 European centres for transcatheter PVL closure in 2017-2019 were included in a prospective registry (Fermeture de Fuite ParaProthétique, FFPP) and followed over 2 years

NCT ID: NCT05088291 Completed - Clinical trials for Coronary Heart Disease

Application of a New X-ray Protective Device in Coronary Interventional Therapy

Start date: September 30, 2021
Phase:
Study type: Observational

This is a multi-center, prospective and controlled clinical trial which will enroll 200 coronary arteriography or percutaneous coronary intervention with 2-4 interventional cardiologist. The interventional cardiologist performed 100 interventional procedures using either a new protective device (NPD) or a traditional lead clothing (TLC). The cumulative dose outside the NPD or TLC and the first operator at each height (110cm, 90cm, 50cm, 10cm) was measured. The main indicators of the study are the average X-ray shielding efficiency of the NPD and the TLC at four different heights. The investigators will record all operation information in this study.